ACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00010704942026-05-13 · Issuer identity, ticker, exchange, SIC, fiscal year end, and filing inventory.SEC XBRL companyfactsSEC companyfacts for CIK 00010704942026-05-13 · Primary financial facts for revenue, expenses, earnings, cash flow, and balance sheet.Annual reportFY2025 Form 10-K2026-02-26 · Business overview, product mix, pipeline, competition, risks, revenue detail, legal proceedings, and strategy.Quarterly reportQ1 2026 Form 10-Q2026-05-07 · Q1 financial statements, cash and investment securities, and updates after the 10-K.Company earnings releaseQ1 2026 earnings release2026-05-06 · Product sales, guidance, DAYBUE STIX launch, and remlifanserin readout timing.Company earnings releaseFY2025 earnings release2026-02-25 · Full-year sales, 2026 initial guidance, IRA rebate adjustment, and cash/investment baseline.Proxy statement2026 definitive proxy statement2026-04-24 · Ownership, governance, executive compensation, and incentive design.Regulator approval pageFDA DAYBUE approval page2023-03-13 · Regulator confirmation of DAYBUE approval and indication.Regulator clinical summaryFDA DAYBUE Drug Trials Snapshot2023-03-12 · Clinical evidence context for DAYBUE approval.FDA approval packageFDA Nuplazid approval package2016-04-29 · Regulator approval context for pimavanserin/NUPLAZID.FDA safety communicationFDA Nuplazid safety review2018-09-20 · Safety monitoring and regulator context for NUPLAZID.